In the claims:

Please amend the claims as follows:

Please amend claims 8, 16, 26, 37, and 44.

Please add new claims 49-51.

1-7. **(Canceled)**

8. **(Currently amended)** A high yield preparation enriched in biologically active receptor-immunoglobulin fusion protein (receptor-Ig-fusion protein) comprising

a) at least 70% biologically active ~~receptor-immunoglobulin fusion protein~~ (receptor-Ig-fusion protein), and

b) no more than 30% inactive receptor-Ig fusion protein,

obtained by culturing a mammalian host cell transformed with DNA encoding the receptor-Ig fusion protein in a culture system having a temperature of about 27° C to about 35° C, wherein the receptor-Ig fusion protein comprises a member of the TNF family of receptors.

9. **(Canceled)**

10. **(Previously presented)** The preparation of claim 8, wherein the receptor-Ig-fusion protein comprises lymphotoxin-β receptor (LT-β-R)-Ig fusion protein.

11. **(Previously presented)** The preparation of claim 8, wherein the receptor-Ig-fusion protein comprises herpes virus entry mediator (HVEM)-Ig-fusion protein.

12-15. **(Canceled)**

16. **(Currently amended)** A pharmaceutical preparation obtained by

(a) culturing a host cell transformed with DNA encoding a lymphotoxin-β receptor (LT-β-R)-Ig-fusion protein in a culture system having a temperature of about 27° C to about 32 ° C, thereby expressing biologically active LT-β-R-Ig-fusion proteins in a cell culture supernatant;

(b) recovering biologically active LT-β-R-Ig-fusion proteins from said cell culture supernatant, wherein said cell culture supernatant comprises at least 70% LT-β-R-Ig-fusion proteins ~~culture system~~; and

(c) combining the biologically active LT-β-R-Ig-fusion proteins recovered from ~~of~~ step (b) with a pharmaceutically acceptable carrier.

17-25. **(Canceled)**

26. **(Currently amended)** A high yield preparation enriched in biologically active receptor-immunoglobulin fusion protein (receptor-Ig-fusion protein) comprising ~~a~~

a) at least 70% biologically active receptor-Ig-fusion protein; and

b) no more than 30% inactive receptor-Ig fusion protein,

obtained by culturing yeast transformed with DNA encoding the receptor-Ig-fusion protein in a culture system having a temperature of about 10° C to about 25° C, wherein the receptor-Ig fusion protein comprises a member of the TNF family of receptors.

27. **(Canceled)**

28. **(Previously presented)** The preparation of claim 26, wherein the receptor-Ig-fusion protein comprises LT-β-R-Ig-fusion protein.

29. **(Previously presented)** The preparation of claim 26, wherein the receptor-Ig-fusion protein comprises HVEM-Ig-fusion protein.

30-36. **(Canceled)**

37. **(Currently amended)** A high yield preparation enriched in biologically active receptor-Ig fusion protein comprising at least 70% biologically active HVEM-Ig-fusion protein ~~proteins~~ obtained by culturing a mammalian host cell transformed with DNA encoding the HVEM-Ig-fusion protein in a culture system having a temperature of about 27° C to about 35 ° C.

38. **(Previously presented)** The preparation of claim 37, wherein the culture system has a temperature of about 27° C to about 32 ° C.

39. **(Previously presented)** The preparation of any one of claims 8, 10, and 11, wherein the culture system has a temperature of about 27° C to about 32 ° C.

40. **(Previously presented)** The preparation of claim 8 or 10, wherein the host cell is a Chinese hamster ovary (CHO) cell or a COS cell.

41. **(Previously presented)** The preparation of claim 16, wherein the host cell is a CHO cell or a COS cell.

42. **(Previously presented)** The preparation of claim 8 or 10, wherein the preparation is a cell culture supernatant.

43. **(Previously presented)** The preparation of claim 8, wherein the preparation comprises at least 83% biologically active receptor-Ig-fusion protein.

44. **(Currently amended)** A high yield preparation enriched in biologically active receptor-Ig fusion protein comprising at least 70% biologically active LT-β-R-Ig-fusion protein obtained by culturing a mammalian host cell transformed with DNA encoding the LT-β-R-Ig-fusion protein in a culture system having a temperature of about 27° C to about 35 ° C.

45. **(Previously presented)** The preparation of claim 44, wherein the culture system has a temperature of about 27° C to about 32 ° C.

46. **(Previously presented)** The preparation of claim 44, wherein the host cell is a CHO cell or a COS cell.

47. **(Previously presented)** The preparation of claim 44, wherein the preparation is a cell culture supernatant.

48. **(Previously presented)** The preparation of claim 44, wherein the preparation comprises at least 83% biologically active LTβ-R-Ig-fusion protein.

49. **(New)** A highly enriched cell culture supernatant obtained by culturing a mammalian host cell transformed with DNA encoding a receptor-Ig fusion protein in a culture system having a temperature of about 27° C to about 35° C comprising

a) at least 70% biologically active receptor-Ig-fusion protein; and

b) no more than 30% inactive receptor-Ig fusion protein,

wherein the receptor-Ig fusion protein comprises a member of the TNF family of receptors and the supernatant has improved ligand binding relative to a high temperature supernatant obtained by culturing a mammalian host cell transformed with DNA encoding the receptor-Ig fusion protein in a culture system having a temperature greater than about 35° C.

50. **(New)** A high yield preparation enriched in biologically active receptor-Ig fusion protein comprising no more than 17% biologically inactive LT-β-R-Ig-fusion protein obtained by culturing a mammalian host cell transformed with DNA encoding the LT-β-R-Ig-fusion protein in a culture system having a temperature of about 27° C to about 35 ° C.

51. **(New)** The preparation of claim 50, comprising no more than 10% biologically inactive LT-β-R-Ig-fusion protein.